167 related articles for article (PubMed ID: 18922853)
41. Transforming growth factor beta3 inhibits chronic myelogenous leukemia hematopoiesis by inducing Fas-independent apoptosis.
Fogli M; Carlo-Stella C; Curti A; Ratta M; Tazzari PL; Ragazzi E; Colla S; Santucci AM; Tura S; Lemoli RM
Exp Hematol; 2000 Jul; 28(7):775-83. PubMed ID: 10907639
[TBL] [Abstract][Full Text] [Related]
42. Targeting of GSK3β promotes imatinib-mediated apoptosis in quiescent CD34+ chronic myeloid leukemia progenitors, preserving normal stem cells.
Reddiconto G; Toto C; Palamà I; De Leo S; de Luca E; De Matteis S; Dini L; Passerini CG; Di Renzo N; Maffia M; Coluccia AM
Blood; 2012 Mar; 119(10):2335-45. PubMed ID: 22262776
[TBL] [Abstract][Full Text] [Related]
43. Natural killer cell immunodeficiency in patients with chronic myelogenous leukemia. IV. Interleukin-1 deficiency, gamma-interferon deficiency and the restorative effects of short-term culture in the presence of interleukin-2 on natural killer cytotoxicity, natural killer-target binding and production of natural killer cytotoxic factor.
Chang WC; Hsiao MH; Pattengale PK
Nat Immun Cell Growth Regul; 1991; 10(2):57-70. PubMed ID: 1881400
[TBL] [Abstract][Full Text] [Related]
44. Aryl hydrocarbon receptor (AHR) is a novel druggable pathway controlling malignant progenitor proliferation in chronic myeloid leukemia (CML).
Gentil M; Hugues P; Desterke C; Telliam G; Sloma I; Souza LEB; Baykal S; Artus J; Griscelli F; Guerci A; Johnson-Ansah H; Foudi A; Bennaceur-Griscelli A; Turhan AG
PLoS One; 2018; 13(8):e0200923. PubMed ID: 30091999
[TBL] [Abstract][Full Text] [Related]
45. The proteasome inhibitor bortezomib disrupts tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) expression and natural killer (NK) cell killing of TRAIL receptor-positive multiple myeloma cells.
Feng X; Yan J; Wang Y; Zierath JR; Nordenskjöld M; Henter JI; Fadeel B; Zheng C
Mol Immunol; 2010 Aug; 47(14):2388-96. PubMed ID: 20542572
[TBL] [Abstract][Full Text] [Related]
46. Chronic myeloid leukemia stem cells possess multiple unique features of resistance to BCR-ABL targeted therapies.
Jiang X; Zhao Y; Smith C; Gasparetto M; Turhan A; Eaves A; Eaves C
Leukemia; 2007 May; 21(5):926-35. PubMed ID: 17330101
[TBL] [Abstract][Full Text] [Related]
47. Distinct molecular phenotype of malignant CD34(+) hematopoietic stem and progenitor cells in chronic myelogenous leukemia.
Kronenwett R; Butterweck U; Steidl U; Kliszewski S; Neumann F; Bork S; Blanco ED; Roes N; Gräf T; Brors B; Eils R; Maercker C; Kobbe G; Gattermann N; Haas R
Oncogene; 2005 Aug; 24(34):5313-24. PubMed ID: 15806158
[TBL] [Abstract][Full Text] [Related]
48. Selective and effective targeting of chronic myeloid leukemia stem cells by topoisomerase II inhibitor etoposide in combination with imatinib mesylate in vitro.
Liu MY; Wang WZ; Liao FF; Wu QQ; Lin XH; Chen YH; Cheng L; Jin XB; Zhu JY
Cell Biol Int; 2017 Jan; 41(1):16-23. PubMed ID: 27677634
[TBL] [Abstract][Full Text] [Related]
49. Bortezomib and flavopiridol interact synergistically to induce apoptosis in chronic myeloid leukemia cells resistant to imatinib mesylate through both Bcr/Abl-dependent and -independent mechanisms.
Dai Y; Rahmani M; Pei XY; Dent P; Grant S
Blood; 2004 Jul; 104(2):509-18. PubMed ID: 15039284
[TBL] [Abstract][Full Text] [Related]
50. HLA-DRB1*16-restricted recognition of myeloid cells, including CD34+ CML progenitor cells.
Ebeling SB; Ivanov R; Hol S; Aarts TI; Hagenbeek A; Verdonck LF; Petersen EJ
Br J Haematol; 2003 Jun; 121(5):721-9. PubMed ID: 12780786
[TBL] [Abstract][Full Text] [Related]
51. The proteasome inhibitor bortezomib interacts synergistically with histone deacetylase inhibitors to induce apoptosis in Bcr/Abl+ cells sensitive and resistant to STI571.
Yu C; Rahmani M; Conrad D; Subler M; Dent P; Grant S
Blood; 2003 Nov; 102(10):3765-74. PubMed ID: 12893773
[TBL] [Abstract][Full Text] [Related]
52. 5-Fluorouracil-resistant CD34+ cell population from peripheral blood of CML patients contains BCR-ABL-negative progenitor cells.
Jazwiec B; Mahon FX; Pigneux A; Pigeonnier V; Reiffers J
Exp Hematol; 1995 Dec; 23(14):1509-14. PubMed ID: 8542939
[TBL] [Abstract][Full Text] [Related]
53. Bortezomib and sphingosine kinase inhibitor interact synergistically to induces apoptosis in BCR/ABl+ cells sensitive and resistant to STI571 through down-regulation Mcl-1.
Li QF; Yan J; Zhang K; Yang YF; Xiao FJ; Wu CT; Wang H; Wang LS
Biochem Biophys Res Commun; 2011 Feb; 405(1):31-6. PubMed ID: 21195056
[TBL] [Abstract][Full Text] [Related]
54. BCR/ABL-negative progenitors are enriched in the adherent fraction of CD34+ cells circulating in the blood of chronic phase chronic myeloid leukemia patients.
Grand FH; Marley SB; Chase A; Titley I; Healy L; Spencer A; Reiter A; Goldman JM; Gordon MY
Leukemia; 1997 Sep; 11(9):1486-92. PubMed ID: 9305602
[TBL] [Abstract][Full Text] [Related]
55. [A preliminary study on mechanisms for resistance of CML patient BM-derived bcr/abl+ and Flk1+CD31-CD34- stem cells to STI571 in vitro].
Song YP; Fang BJ; Wei XD; Zheng S
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2005 Dec; 13(6):1004-9. PubMed ID: 16403268
[TBL] [Abstract][Full Text] [Related]
56. Expression differences of genes in the PI3K/AKT, WNT/b-catenin, SHH, NOTCH and MAPK signaling pathways in CD34+ hematopoietic cells obtained from chronic phase patients with chronic myeloid leukemia and from healthy controls.
de Cássia Viu Carrara R; Fontes AM; Abraham KJ; Orellana MD; Haddad SK; Palma PVB; Panepucci RA; Zago MA; Covas DT
Clin Transl Oncol; 2018 Apr; 20(4):542-549. PubMed ID: 28905209
[TBL] [Abstract][Full Text] [Related]
57. Effect of Age on NK Cell Compartment in Chronic Myeloid Leukemia Patients Treated With Tyrosine Kinase Inhibitors.
Rodrigues-Santos P; López-Sejas N; Almeida JS; Ruzičková L; Couceiro P; Alves V; Campos C; Alonso C; Tarazona R; Freitas-Tavares P; Solana R; Santos-Rosa M
Front Immunol; 2018; 9():2587. PubMed ID: 30487792
[TBL] [Abstract][Full Text] [Related]
58. CXCR4 up-regulation by imatinib induces chronic myelogenous leukemia (CML) cell migration to bone marrow stroma and promotes survival of quiescent CML cells.
Jin L; Tabe Y; Konoplev S; Xu Y; Leysath CE; Lu H; Kimura S; Ohsaka A; Rios MB; Calvert L; Kantarjian H; Andreeff M; Konopleva M
Mol Cancer Ther; 2008 Jan; 7(1):48-58. PubMed ID: 18202009
[TBL] [Abstract][Full Text] [Related]
59. Role of natural killer cells for immunotherapy in chronic myeloid leukemia (Review).
Lee HR; Baek KH
Oncol Rep; 2019 May; 41(5):2625-2635. PubMed ID: 30896812
[TBL] [Abstract][Full Text] [Related]
60. Imatinib and bortezomib induce the expression and distribution of anaphase-promoting complex adaptor protein Cdh1 in blast crisis of chronic myeloid leukemia.
Wang Q; Zhou HS; Huang KK; Jiang XJ; Wu FQ; Cao R; Yin CX; Liao LB; Zheng ZX; He H; Lin R; Yi ZS; Xu D; Yang M; Meng FY
Int J Oncol; 2012 Feb; 40(2):418-26. PubMed ID: 22002244
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
